Compare Expensify Inc (EXFY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Novavax Inc — how do they compare? Expensify Inc trades at $2.27 (market cap $209.73M), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 6.2× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | NVAX | |
|---|---|---|
Market Cap | $209.73M | $1.31B |
Sector | Technology | Health |
52-Week High | $2.69 | $11.19 |
52-Week Low | $0.75 | $6.22 |
Enterprise Value | $149.35M | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.22, down 10.12% in the past 24 hours, with a bullish technical signal from moving averages and a neutral RSI. Recent Q2 2026 earnings showed a beat on EPS and a return to non-GAAP profitability, with revenue of $33.9 million. The company is expanding its AI-native solutions and European card offerings, supported by positive cash flow trends.
Outlook is cautiously optimistic due to earnings improvements and strategic expansions, but risks include persistent net losses, high P/E ratio of 258.82, and competitive pressures in expense management software. Analyst consensus is mixed with 44% buy ratings.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
